Phoenix, United States
Beacon Biomedical, founded in 2014 in the United States, operates at the forefront of the Biotechnology and Health Care industries. The company boasts a compelling slogan: "Easy, Accurate & Affordable Blood Based Screening for early detection of cancer and COVID-19 detection and antibodies," which succinctly encapsulates its mission.
As a molecular proteomic diagnostics company, Beacon Biomedical is committed to the development and commercialization of CLIA laboratory and point-of-care CLIA waived tests aimed at earlier cancer detection. Its flagship product, BeScreened™-CRC, is a pioneering blood-based test designed for the early detection of colorectal cancer. Furthermore, its robust product pipeline targets early detection of other prevalent cancers, including breast, lung, prostate, and ovarian cancers.
Despite the absence of recent investment data, the company's innovative approach and focus on accessibility position it as a potential disrupter in the cancer diagnostics space.
